title: Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspective.
abstract: The incidence of type 2 diabetes (T2DM) is rapidly increasing worldwide. However, the pathogenesis of T2DM has not yet been well explained. Recent evidence suggests that the intestinal microbiota composition is associated with obesity and T2DM. In this review, we provide an overview about the mechanisms underlying the role of intestinal microbiota in the pathogenesis of T2DM. There is clear evidence that the intestinal microbiota influences the host through its effect on body weight, bile acid metabolism, proinflammatory activity and insulin resistance, and modulation of gut hormones. Modulating gut microbiota with the use of probiotics, prebiotics, antibiotics, and fecal microbiota transplantation may have benefits for improvement in glucose metabolism and insulin resistance in the host. Further studies are required to increase our understanding of the complex interplay between intestinal microbiota and the host with T2DM. Further studies may be able to boost the development of new effective therapeutic approaches for T2DM.
authors.affiliation: Jun-Ling Han, Hui-Ling Lin, Department of Endocrinology and Metabolism, the 187 Hospital of PLA, Haikou 571159, Hainan Province, China.
authors.forename: Jun-Ling
authors.initials: JL
authors.lastname: Han
authors.affiliation: Jun-Ling Han, Hui-Ling Lin, Department of Endocrinology and Metabolism, the 187 Hospital of PLA, Haikou 571159, Hainan Province, China.
authors.forename: Hui-Ling
authors.initials: HL
authors.lastname: Lin
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001419:Bacteria / Q000145:classification / Q000187:drug effects / Q000254:growth & development*; D001647:Bile Acids and Salts / Q000378:metabolism; D001835:Body Weight; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism / Q000382:microbiology* / Q000503:physiopathology / Q000628:therapy; D005768:Gastrointestinal Hormones / Q000378:metabolism; D054884:Host-Pathogen Interactions; D006801:Humans; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000382:microbiology* / Q000503:physiopathology; D064307:Microbiota; D065626:Non-alcoholic Fatty Liver Disease / Q000378:metabolism / Q000382:microbiology; D056692:Prebiotics; D019936:Probiotics / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D001647:Bile Acids and Salts; D005768:Gastrointestinal Hormones; D007328:Insulin; D056692:Prebiotics
keywords: Bile-acid metabolism; Body weight; Insulin resistance; Intestinal microbiota; Intestinal microbiota modulation; Type 2 diabetes